BCRP/ABCG2 Inhibition Sensitizes Hepatocellular Carcinoma Cells to Sorafenib

The multikinase inhibitor, sorafenib (Nexavar®, BAY43-9006), which inhibits both the Raf/MEK/ERK pathway and several receptor tyrosine kinases (RTKs), has shown significantly therapeutic benefits in advanced hepatocellular carcinoma (HCC). However, not all HCC patients respond to sorafenib well and...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Huang, Wei-Chien, Hsieh, Yi-Ling, Hung, Chao-Ming, Chien, Pei-Hsuan, Chien, Yu-Fong, Chen, Lei-Chin, Tu, Chih-Yen, Chen, Chia-Hung, Hsu, Sheng-Chieh, Lin, Yueh-Ming, Chen, Yun-Ju
Médium: Artigo
Jazyk:Inglês
Vydáno: Public Library of Science 2013
Témata:
Research Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3877048/
https://ncbi.nlm.nih.gov/pubmed/24391798
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0083627
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky